This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-10. Anything still debated is marked as such rather than presented as settled.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
=== Differential diagnosis === Symptoms of early scabies infestation mirror other skin diseases, including dermatitis, syphilis, erythema multiforme, various urticaria-related syndromes, allergic reactions, ringworm-related diseases, and other ectoparasites such as lice and fleas.
210Po is extremely toxic; it and other polonium isotopes are some of the most radiotoxic substances to humans. With one microgram of 210Po being more than enough to kill the average adult, it is 250,000 times more toxic than hydrogen cyanide by weight. This is a consequence of its ionizing alpha radiation, as alpha particles are especially damaging to organic tissues inside the body. However, 210Po does not pose a radiation hazard when kept outside the body. The alpha particles it produces cannot penetrate the outer layer of dead skin cells. The toxicity of 210Po stems entirely from its radioactivity. It is not chemically toxic in itself, but its solubility in aqueous solution as well as that of its salts poses a hazard because its spread throughout the body is facilitated in solution. Intake of 210Po occurs primarily through contaminated air, food, or water, as well as through open wounds. Once inside the body, 210Po concentrates in soft tissues (especially in the reticuloendothelial system) and the bloodstream. Its biological half-life is approximately 50 days. In the environment, 210Po can accumulate in seafood. It has been detected in various organisms in the Baltic Sea, where it can propagate in, and thus contaminate, the food chain. 210Po is also known to contaminate vegetation, primarily originating from the decay of atmospheric radon-222 and absorption from soil. In particular, 210Po attaches to, and concentrates in, tobacco leaves.
=== France trip === In June 2026, Peters made a trip to Paris, where he modeled at the Fashion Week opening and attended the Fête de la Musique. Clips from his livestream showing him attempting, without success, to engage with women subsequently went viral in France, drawing ridicule from netizens and French media. Madame Figaro described Peters as being "massively rejected" by Parisian women. Le Monde commented that the "masculinist influencer" who "set out to test his self-proclaimed 'alpha male' magnetism on Parisian women" was "only met with indifference or disdain." In one video, Peters expressed confusion about his lack of success in Paris and theorized that the French women who appeared uninterested in him were probably "lesbians". In later messages, he called the French "impolite shitbags", mocked France's quality of living and stated that European women were less attractive than American ones due to Europe's gene pool being "devastated" in World War II. After Paris, Peters visited the French Riviera. He initially expressed appreciation for Saint-Tropez, but later called the city "retarded". In Cannes, he was denied access to a venue, and heckled in the street by a woman who called him a "Nazi" and told him he was "not welcome" in France.
== Legacy == David Lipman, director of the National Center for Biotechnology Information, has called Dayhoff the "mother and father of bioinformatics". Her seminal contributions as the mother of the science of bioinformatics, now routinely used as part of the process for naming bacteria, were acknowledged with a bacterium being named after her in 2020, Enemella dayhoffiae. Dayhoff was inducted into the Maryland Women's Hall of Fame in March 2026.
Sources: en.wikipedia.org
==== Delirium ==== A systematic review, published in 2014, concluded "ramelteon was found to be beneficial in preventing delirium in medically ill individuals when compared to placebo." A 2022 systematic review and meta-analysis found that the combination of ramelteon and the orexin receptor antagonist suvorexant may reduce the incidence of delirium in adults hospitalized patients whereas suvorexant alone was ineffective.
Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals. The most common side effects include infections, low levels of white blood cells, headache, cough, nausea (feeling sick), vomiting, diarrhea, constipation, tiredness, hair loss and rash. Ribociclib was approved for medical use in the United States in March 2017, in the European Union in August 2017, and in the United Kingdom in February 2021.
A family history of the disease Higher incidence in males Palmar fibromatosis 10–65% of the time. Peyronie's disease Epilepsy patients Diabetes mellitus There is also a suspected, although unproven, link between incidence and alcoholism, smoking, liver diseases, thyroid problems, and stressful work involving the feet.
Sources: en.wikipedia.org
Lipases are a type of enzyme that break down fats. More specifically, lipases use water (as hydrolases) to remove fatty acids from fat molecules, especially triglycerides or its derivatives. In humans and other animals, lipases have a variety of roles in the body, from helping digest dietary fats like pancreatic lipase, to synthesizing fat-based hormones like diglyceride lipases. What counts as a lipase is not consistently defined across sources, and some only consider enzymes to be lipases if they are activated by oil-water interfaces. Many specific lipases can also catalyze other reactions. For example, carboxyl ester lipase is able to remove fatty acids that are attached to cholesterol, while endothelial lipase can remove fatty acids from phospholipids (a major component of cell membranes).
This enables researchers to report a ratio for the expression of the genes of interest divided by the expression of the selected normalizer, thereby allowing comparison of the former without actually knowing its absolute level of expression. The most commonly used normalizing genes are those that code for the following molecules: tubulin, glyceraldehyde-3-phosphate dehydrogenase, albumin, cyclophilin, and ribosomal RNAs.
Donald McKain, Staff Side Coordinator, Grampian Healthcare NHS Trust. For services to Health Care. Neil McKay, Revenue Executive, Board of Inland Revenue. Stuart William McKay. For services to the de Havilland Moth Club. Evelyn Hildegard McKinley, Administrative Officer, Ministry of Defence. Norman McLean, Director, National Mentoring Consortium. For services to the Ethnic Community. Richard Dick McLean, Prison Officer, Her Majesty's Prison, Edinburgh. Carol Ross McNeilage, Nursing Auxiliary, Vale of Leven Hospital, Alexandria. For services to Health Care and to the community. Valerie Matilda McNeill. For services to the Ports Industry. Paul McStay. For services to Association Football. Joseph Henry McWhirter. For services to the community and to the Post Office. Ivy Florence Medley. For services to the community in St Lawrence, Essex. Jeremiah Joseph Mee. For services to the Sick Dentist Scheme. David Klemman Meeker. For services to the National Film and Television Archive. Bridget Anne Meyer, Higher Executive Officer, Commonwealth War Graves Commission. Rolf Meyer. For services to the community in Brixham, Devon. Donald John Milburn. For services to the Police and to the community. Evelyn May Miller, Administrative Officer, Ministry of Defence. Nicholas Charles Miller. For services to People with Alcohol Problems. Sheila Denise Miller. For services to the British Tourist Authority. Squadron Leader Raymond Mills. For services to the community in Cambridgeshire. Ena Montgomery. For services to the community in Chorley, Lancashire. Robert Joseph Montgomery.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.